Tags

Type your tag names separated by a space and hit enter

Cisapride and ranitidine in the treatment of gastro-oesophageal reflux disease--a comparative randomized double-blind trial.
Aliment Pharmacol Ther 1993; 7(6):635-41AP

Abstract

Forty patients with gastro-oesophageal reflux disease and oesophagitis, documented by endoscopy (grades I to III by the Savary-Miller classification) were randomized to participate in a comparative double-blind trial to receive cisapride (10 mg q.d.s.) or ranitidine (150 mg b.d.) for an 8-week period. Upper gastrointestinal endoscopy was performed immediately before the entry to the trial and after the 8-week period at the completion of the trial. The evaluable cohort included 37 patients who completed the trial, 18 in the cisapride group and 19 in the ranitidine group. Three patients were withdrawn from the trial; one on ranitidine developed severe anaphylactic reaction, one on cisapride severe dizziness and one on cisapride did not wish to continue on the trial. The results of the trial, regarding symptomatic and endoscopic improvement were comparable in the two groups. Both drugs were effective in controlling symptoms, such as acid regurgitation, retrosternal pain, retrosternal burning, epigastric fullness and discomfort (pain, burning, sense of pressure) and resulted in endoscopic healing of oesophagitis. With few exceptions, symptoms remained in remission 1 month after treatment in the majority of patients. Globally, both drugs were tolerated comparably, and adverse effects other than those which resulted in the withdrawal from the trial were minimal in both groups. The results of this trial indicate that cisapride and ranitidine, although of different pharmacological action, are comparable in their therapeutic effect in symptomatic improvement and endoscopic healing in patients with mild to moderate gastro-oesophageal reflux disease.

Authors+Show Affiliations

First Department of Medicine, University of Thessaloniki School of Medicine, AHEPA General Hospital, Greece.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

8161670

Citation

Arvanitakis, C, et al. "Cisapride and Ranitidine in the Treatment of Gastro-oesophageal Reflux Disease--a Comparative Randomized Double-blind Trial." Alimentary Pharmacology & Therapeutics, vol. 7, no. 6, 1993, pp. 635-41.
Arvanitakis C, Nikopoułos A, Theoharidis A, et al. Cisapride and ranitidine in the treatment of gastro-oesophageal reflux disease--a comparative randomized double-blind trial. Aliment Pharmacol Ther. 1993;7(6):635-41.
Arvanitakis, C., Nikopoułos, A., Theoharidis, A., Giannoulis, E., Vagios, I., Anthopoulou, H., ... Tourkantonis, A. (1993). Cisapride and ranitidine in the treatment of gastro-oesophageal reflux disease--a comparative randomized double-blind trial. Alimentary Pharmacology & Therapeutics, 7(6), pp. 635-41.
Arvanitakis C, et al. Cisapride and Ranitidine in the Treatment of Gastro-oesophageal Reflux Disease--a Comparative Randomized Double-blind Trial. Aliment Pharmacol Ther. 1993;7(6):635-41. PubMed PMID: 8161670.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cisapride and ranitidine in the treatment of gastro-oesophageal reflux disease--a comparative randomized double-blind trial. AU - Arvanitakis,C, AU - Nikopoułos,A, AU - Theoharidis,A, AU - Giannoulis,E, AU - Vagios,I, AU - Anthopoulou,H, AU - Michailidis,D, AU - Tourkantonis,A, PY - 1993/12/1/pubmed PY - 1993/12/1/medline PY - 1993/12/1/entrez SP - 635 EP - 41 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 7 IS - 6 N2 - Forty patients with gastro-oesophageal reflux disease and oesophagitis, documented by endoscopy (grades I to III by the Savary-Miller classification) were randomized to participate in a comparative double-blind trial to receive cisapride (10 mg q.d.s.) or ranitidine (150 mg b.d.) for an 8-week period. Upper gastrointestinal endoscopy was performed immediately before the entry to the trial and after the 8-week period at the completion of the trial. The evaluable cohort included 37 patients who completed the trial, 18 in the cisapride group and 19 in the ranitidine group. Three patients were withdrawn from the trial; one on ranitidine developed severe anaphylactic reaction, one on cisapride severe dizziness and one on cisapride did not wish to continue on the trial. The results of the trial, regarding symptomatic and endoscopic improvement were comparable in the two groups. Both drugs were effective in controlling symptoms, such as acid regurgitation, retrosternal pain, retrosternal burning, epigastric fullness and discomfort (pain, burning, sense of pressure) and resulted in endoscopic healing of oesophagitis. With few exceptions, symptoms remained in remission 1 month after treatment in the majority of patients. Globally, both drugs were tolerated comparably, and adverse effects other than those which resulted in the withdrawal from the trial were minimal in both groups. The results of this trial indicate that cisapride and ranitidine, although of different pharmacological action, are comparable in their therapeutic effect in symptomatic improvement and endoscopic healing in patients with mild to moderate gastro-oesophageal reflux disease. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/8161670/Cisapride_and_ranitidine_in_the_treatment_of_gastro_oesophageal_reflux_disease__a_comparative_randomized_double_blind_trial_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0269-2813&date=1993&volume=7&issue=6&spage=635 DB - PRIME DP - Unbound Medicine ER -